We see a world where targeted therapies may alter the course of cancer for millions of patients.
Aprea Therapeutics embraces the latest advancements in precision medicine and targeted cancer therapies. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects.
Specifically, we develop small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and intended to make treatments more effective at destroying cancer cells while sparing healthy tissue.
Aprea believes that its unique approach may revolutionize the future of cancer treatment. We designed our lead small molecule therapeutic, WEE1 inhibitor (APR-1051), to maximize clinical activity while minimizing toxicity through increased selectivity.
Aprea’s robust pipeline is led by APR-1051, currently in active clinical trials, alongside ATRN-119 and additional DDR-targeted programs to improve our chances of success. We are committed to broadening the scope of our therapeutic portfolio to give patients renewed hope for beating cancer.
Every day we advance our clinical trials, we are one step closer to bringing DDR-targeted therapies to market. Our goal is to benefit the greatest number of cancer patients possible.
3805 Old Easton Rd
Doylestown, PA 18902
Copyright © 2026 Aprea Therapeutics. All Rights Reserved.
cookieyes-site-verification=Xt9Nv2Wq5L-Po7Rs1GcVm3Hb8Ye4QdKf-AzBj650Mny